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Purpose. Since fear of falling may be one of the main problems in people with Parkinson’s disease (PD), its assessment with valid
tools is necessary in both drug phases. /is study was carried out to investigate the psychometric attributes of the Fall Efficacy
Scale-International (FES-I) in people with PD, both in On and Off phases. Methods. One hundred twenty-four patients with PD
(mean age ± standard deviation, 60.33 ± 12.59 years) were assessed with the FES-I, both in On- and Off-drug phases. Di-
mensionality, internal consistency, and test-retest reliability were, respectively, explored by means of factor analysis, Cronbach’s
alpha, and Intraclass Correlation Coefficient. Convergent validity of FES-I was established with Visual Analog Scale-Fear of
Falling, Berg Balance Scale, and Functional Reach Test. Parkinson’s Disease Questionnaire-39 and Unified Parkinson Disease
Rating Scale-Activities of Daily Living were also applied. Discriminative validity was tested between patients with and without a
history of falling. Results. Factor analysis showed two factors for On- and one factor for Off-drug phase. Internal consistency (α �
0.96, On phase; 0.98, Off phase) and test-retest reliability (0.94; 0.91) were satisfactory in both drug phases. /ere was a moderate/
high correlation (rS � |0.50–0.70|) between FES-I and Visual Analog Scale-Fear of Falling, Berg Balance Scale, and Functional
Reach Test. Parkinson’s Disease Questionnaire-39 and Unified Parkinson Disease Rating Scale-Activities of Daily Living were
achieved in both drug phases too. /e sensitivity of FES-I to discriminate Parkinson’s disease with and without falls showed
moderate effect size in both phases. Conclusion. /is study verified that FES-I is unidimensional, reliable, and valid to measure the
Fear of Falling during On- and Off-drug phases in people with PD.
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1. Introduction
Fear of falling (FOF) in Parkinson’s disease (PD) is known to
be a common problem affecting about 45 to 68 percent in
this population [1]. FOF is defined as a reduction in certainty
in doing activities without falling (loss of self-efficacy) [2]. It
may not cause disorder in daily-life by itself, but the
avoidance of doing daily activities, reduction in the amount
of physical activities, and increase in the risk of falling are
among its serious consequences [3, 4]. In addition, the
psychological impact of FOF can increase the patients’ social
isolation [5]. /e detrimental effect of FOF on the quality of
life of individuals prompts to consider this disorder an
important problem requiring monitoring and treatment
[6, 7].
Levodopa is the main gold standard treatment of PD and
can be beneficial for almost all people with PD. However, as
the disease progresses, continuous use of the drug can lead to
a series of motor complications (motor fluctuations and
dyskinesia). Motor fluctuations refer to oscillations between
two drug phases called “On” (when the motor symptoms are
controlled by the medication) and “Off” (when the motor
symptoms reemerge uncontrolled by the medication) [8, 9].
Various studies have examined the effects of motor fluc-
tuations in both drug phases on various performances such
as balance and falling in patients who develop this com-
plication. It has been shown that reducing the amount of
levodopa (reaching to Off-drug phase) may cause stride time
variability and increase the intensity of fear of falling and
subsequent falling, which could influence results in Off state
[10–12].
Several instruments have been designed to assess the fear
of falling while doing daily activities [13–15]. Among these
scales, Activity Balance Confidence (ABC), Fall Efficacy
Scale (FES), Survey of Activities and Fear of Falling in the
Elderly (SAFE), and Fall Efficacy Scale-International (FES-I)
can be mentioned valid and reliable in PD during On-drug
phase. /e ABC scale measures the level of balance confi-
dence while doing 16 activities without falling. ABC scale has
been used widely although it contains items (such as icy
pavements) that can be culturally not applicable in all
populations. /e FES is a well-validated and short scale that
contains 10 items and measures the level of concern for
falling during specific daily activities. Unfortunately, this
scale does not consider social activities [16]. /e SAFE scale
consists of 17 items that measure the individual’s avoidance
of a series of activities. /e main weakness of this scale is the
length that may turn it impractical in some sitting [17]. One
of other tools is the Fall Efficacy Scale-International (FES-I),
an instrument designed by Yardley et al. in 2005. /is 16-
item scale has appropriate psychometric properties in elder
population to measure the extent of concern caused by
falling at the time of doing daily activities [18]. /is scale has
also been studied in people with stroke, MS, osteoporosis,
and dizziness and postmenopausal women [19–22]. It was
hypothesized that FES-I would be strongly correlated with
scales estimating balance and would show moderate to high
association with disability measures. Previous studies for
dimensionality of FES-I have reported two factors (indoor
and outdoor activities) in other populations [18, 22–24].
Also, with a cut-off point of 21 in FES-I total score, subjects
could be divided to two groups of high and low level of fear
of falling [25].
Recent studies investigated the test-retest reliability and
the ability of the FES-I (and other tools for measuring FOF)
for detecting PD patients with falling records during the
“On” phase [26, 27]. Nevertheless, a reliable and valid in-
strument is required to show the extent of changes in re-
habilitation and drug treatments in both drug phases [12].
While most studies in PD population have been conducted
to investigate the psychometric properties of the assessment
tools in “On” phase, it is unknown whether changes in the
motor symptoms of patients during the “Off” phase alter the
psychometric properties of the tools. /erefore, we aimed to
investigate the psychometric properties (such as accept-
ability, dimensionality, internal consistency, test-retest re-
liability, and convergent and discriminative validity) of the
FES-I in people with PD during both “On-” and “Off-”drug
phases.
2. Methods
2.1. Subjects. One hundred twenty-four people with PD
referred to movement disorder clinic in Rasoul Akram
Hospital were included. Inclusion criteria were diagnosis of
PD based on the UK brain bank criteria [28], fluency in
Persian language, absence of evident cognitive problem
(Minimal Mental Status Examination >21) [29], lack of other
neurologic and orthopedic diseases (such as stroke, severe
arthritis, lower limb fracture, etc.), and fixed dose of
medication use (Levodopa and other dopamine agonists)
until the time of retest.
All subjects signed the informed consent to take part in
the project. /e study protocol was approved by the ethics
committee of the Student Research Committee in Iran
University of Medical Sciences.
2.2. Assessments. /e Persian version of the FES-I has been
previously shown to have adequate reliability and validity in
Iranian elder population [30, 31]. FES-I has 16 items that
assess persons concern about falling during daily activities.
Every item is scored from 0 to 4 and the maximum total
score of the scale is 64, a figure representing person’s fear of
falling while doing activity [18].
In order to assess the convergent validity of the FES-I in
both “On-” and “Off-”drug phases, we also assessed other
PD disturbances relevant to falling, namely, balance, quality
of life, and activities of daily living. For this purpose, the
following assessments with random order were applied:
Visual Analog Scale-Fear of Falling (VAS-FOF), Berg Bal-
ance Scale (BBS), Functional Reach Test (FRT), Parkinson’s
Disease Questionnaire-39 (PDQ-39), and Unified Parkinson
Disease Rating Scale-Activities of Daily Living (UPDRS-
ADL).
/e VAS-FOF is a numerical scale on which elder in-
dividuals score their fear of falling in the range 0 to 10. In this
scale 10 represents extreme fear of falling [32].
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/e BBS has proper reliability and validity in PD. /is
14-item tool is designed to measure functional balance. /e
total score of BBS ranges from 0 to 56, and greater scores
indicate better balance [33].
/e FRT is used to screen persons for falling risk and to
measure anteroposterior stability in PD [34]. Each subject
performed 3 test trials and the average of these trials is
calculated as FRT score. /e persons with better functional
balance receive higher score [35].
/e PDQ-39 was designed to measure Parkinson’s pa-
tient’s quality of life. PDQ-39 consists of 8 domains (move-
ment, daily-living activities, well-being, motivation, social
support, cognition, communication, and physical discomfort).
Items are scored in the range 0–4, and total scores for domains
are calculated as percentage on themaximum possible score of
their corresponding items, whereas the PDQ-39 summary
index is the mean score of the eight domains. /e lower the
score, the better the quality of life [36].
/e UPDRS-ADL section is commonly used to evaluate
the ability of patients for doing daily-living activities. /is
UPDRS subscale consists of 13 items, with a total score of 0
to 52. Higher scores indicate higher disability [37].
Hoehn and Yahr (HY) scale was designed to determine
the level of disease progression in people with Parkinson’s.
Based on this scale, the severity of disease is divided into 5
levels. At the first level, the condition is normal, and at the
last level, people are wheelchair bound [38].
2.3. Procedures. Patients were assessed by an experienced
occupational therapist through face to face interview using
Persian version of the FES-I, in Off-drug phase (12 hours
after taking the last dose of Levodopa and before taking the
first morning dose [12]) and in On-drug phase (1 hour after
taking Levodopa at first morning dose [12]). All assessments
were applied during On- and Off-drug phases.
/e history of falling in the last 6 months was recorded
by interviewing with people with PD. Accordingly, in-
dividuals were categorized into two groups with and without
history of falling. To evaluate reliability of test-retest, sub-
jects were studied in second session (average interval, 10
days) by the same occupational therapist at the same con-
ditions of first session.
2.4. Data Analysis. Normal distribution of data was tested
using Shapiro–Francia test [39]. Apart descriptive statistics
(mean, standard deviation, and percentage) the following
statistics were used.
Acceptability was determined by floor and ceiling effects
(percentages), with ≤15% values considered acceptable [40].
/e range of skewness deemed acceptable was +1 to −1 [41].
Exploratory factor analysis (EFA) with varimax rotation
was used to investigate the construct validity and di-
mensionality of FES-I. Explained variance of dimension with
Eigenvalues of greater 1 was considered [42].
Internal consistency was determined through Cron-
bach’s alpha, with a value >0.70 considered the minimum
acceptable value [43]. Interitem and corrected item-total
correlations were also calculated, with minimal threshold
values 0.20 [44] and 0.30 [45] deemed acceptable,
respectively.
Test-retest reliability of the FES-I total score was esti-
mated by Intraclass Correlation Coefficient (ICC), two-way,
and single measure, with 95% confidence interval. ICC
values higher than 0.70 represent acceptable reliability [46].
FES-I precision was estimated through its Standard Error of




). SEM values <1/
2 SDpooled are considered acceptable [47].
FES-I convergent validity was explored by correlation
with other measures (VAS-FOF, BBS, FRT, PDQ-39 (Do-
main “Mobility”), and UPDRS-ADL), using Spearman rank
correlation coefficient. Correlation values higher than 0.50,
between 0.35 and 0.50 and less than 0.35 were considered
strong, moderate, and weak correlations, respectively [48]. It
was hypothesized that FES-I would be strongly correlated
with scales for estimating balance, and would show mod-
erate to high association with disability measures.
Discriminative validity between two different groups
(PD patients with and without history of falling during
previous 6 months) was determined by Mann–Whitney test
and Cohen’s d effect size (differences of means divided by
baseline pooled standard deviation). Magnitudes of effect
size 0.2, 0.5, and 0.8 reflect small, moderate, and high
separation power, respectively [49]. It was expected a
moderate to highly significant difference of the FES-I total
score between fallers and nonfallers.
Wilcoxon signed-rank test was applied to compare the
scale scores between the two drug phases (significant level,
p< 0.05) [50].
3. Results
/e mean (±SD) age was 60.33 ± 12.59 years and disease
duration was 6.66 ± 5.51 (Table 1). /irty-four out of the 124
patients (27%) were Hoehn and Yahr (HY) stage 1; 51
patients (40.5%) in stage 2; 39 (31%) in stage 3.
Shapiro–Francia test showed nonnormal distribution of
data, including the total score of the FES-I. Total FES-I
scores were 27.34 and 33.38 for On- and Off-drug phases,
respectively (Table 2). Fifty-three patients (42.7%) had re-
cord of falling (had history of falling during previous six
months), with mean ± SD FES-I scores of 31.56 ± 10.80 and
37.81 ± 15.29 for On- and Off-drug phases, respectively, for
this group.
3.1. Acceptability. /e ceiling effect of the FES-I for both
drug phases was ≥15%, but floor effect was mildly higher
than this threshold (Table 2). /e skewness values were in
the range −1 to +1 for both On- and Off-drug phases.
3.2. Dimensionality. Exploratory factor analysis showed two
factors for On phase and just one factor for Off phase
(Kaiser–Meyer–Olkin � 0.91 and 0.95; Bartlett’s test of
sphericity both p< 0.001) (Table 3). We named the first
factor as “Balance and social activities (outdoor)” which is
including 8 items (7, 8, 9, 11, 13, 14, 15, and 16) and the
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second factor as “Basic personal activities (indoor)” which is
including the remaining items (1, 2, 3, 4, 5, 6, 10, and 12).
3.3. Internal Consistency. Cronbach’s alpha index of the
FES-I was 0.96 for On- and 0.98 for Off-drug phases.
Interitem correlations ranged in On state from 0.40 (Item 10
with items 14, 15, and 16) to 0.97 (Item 1 with item 7) and, in
Off state, from 0.58 (Item 10 with 11) to 0.87 (Item 12 with
item 16). Item homogeneity index was 0.59 for the On and
0.72 for the Off phase.
3.4. Reliability. In regard to the test-retest reliability for total
FES-I scores, ICC values were 0.94 (CI 95% � 0.90–0.96),
and 0.91 (CI 95% � 0.86–0.94) for On- and Off-drug phases,
respectively. SEM calculation on these ICCs was 2.77 and
4.62, respectively, values clearly lower than 1/2 SD at first
application (5.66 in On state and 7.71 in Off state).
3.5. Convergent Validity. /is study revealed strong re-
lationship between total FES-I score and VAS-FOF (r �
0.50–0.54, p< 0.001), tests for functional movement and its
quality (BBS, FRT, PDQ-39 (Mobility) (r � 0.51–0.76,
p< 0.001), and independency in daily activities (UPDRS-
ADL) (r � 0.67, p< 0.001) in both On- and Off-drug phases
(Table 4).
3.6. Discriminative Validity. /e difference in FES-I scores
for Fallers vs Nonfallers in On ((meanF ± SD) 31.56 ± 10.80
vs 4.19 ± 10.72) and in Off, Fallers vs Nonfallers (37.81 ±
15.29 vs 30.43 ± 14.86) were statistically significant
(Mann–Whithney test, p< 0.001 and p≤ 0.005, re-
spectively). Effect size for the FES-I in discriminating
between Fallers and Nonfallers was 0.68 (On drug phase)
and 0.48 (Off-drug phase).
For the complete sample of patients in the study, FES-I
total score was (mean ± SD) 27.34 ± 11.32 in On and 33.38 ±
15.41 in Off state (Wilcoxon test, p≤ 0.001).
4. Discussion
/is study was carried out to assess the main clinimetric
properties of FES-I for both drug phases, On and Off, in
subjects with PD. Our findings revealed that FES-I has high
reliability and acceptable convergent (convergent and dis-
criminant) validity to measure fear of falling in PD during
both On- and Off-drug phases.
In the FES-I (both On- and Off-drug phases), item 11
(Walking on a slippery surface) and item 14 (Walking on an
uneven surface) got the highest mean score, indicating a
greater degree of difficulty, according to past studies [51, 52].
Based on our test-retest results, FES-I total score was
very stable in both drug phases and similar to previous
report in PD populations in which is done only in On-drug
phase (ICC � 0.92) [27]. Regarding the ICC obtained in the
mentioned previous report, the samples were the same in
size and PD duration, but in our data were included “On-”
and “Off-”drug phases separately.
SEM values obtained for FES-I were ≤30% of the
standard deviation at the first application. SEM value in On-
drug phase is close to that obtained in Jonasson’s study
(2017) (SEM � 3.4) [27].
In factor analysis of FES-I total score for the drug on-
phase, similar to previous studies, two dimensions have been
shown (the first factor dominated by basic and instrumental
activities of daily living and the second factor dominated by
physically demanding outdoor activities) [18, 53]. /e re-
sults factor analysis in the Off-drug phase showed unidi-
mensionality of this scale. Possibly, patients with PD and
mobility or stability problems are concerned about falling
during daily activities (home or outdoor), a fact that should
be considered for optimizing the management of those PD
patients.
A strong correlation between total FES-I score and VAS-
FOF revealed that it is reasonable to use either of these tools
to measure fear of falling in both drug phases. In VAS-FOF,
fear of falling is generally evaluated and can be faster. In
contrast, with FES-I, fear of falling in 16 activities can be
estimated with more detail by spending more time. Al-
though both scales are used to assess the fear of falling and
have a strong relationship, they also have advantages and
disadvantages. FES-I score showed strong-association with
other scales measuring balance (BBS, FRT, PDQ-39 (Mo-
bility)) in both drug phases (Table 4). /is finding indicates
the close relationships between fear of falling and disorders
of global mobility in people with Parkinson’s disease that can
be due to the similarities between the evaluated activities on
these scales, such as up and down steps and reaching. Strong
correlation between FES-I total score and scores of scales
measuring independency in daily-living activities (UPDRS-
ADL) showed that fear of falling is associated with re-
striction for performing daily activities in individuals with
Table 1: Demography characteristics of people with PD (n � 124).
Variables Mean (±SD)
Age (year) 60.33(±12.59)
Time since diagnosis (year) 6.66 (±5.51)
Mini mental status examination (score) 23.90 (±2.75)
Variables Frequency(%)
Sex (male) 90 (72.58%)
Current medications
Levodopa 101 (81.45%)
Dopamine agonists 22 (17.74%)












PD and how this factor can contribute to their functional
disability and quality of life deterioration.
Findings from a previous study [27] revealed that FES-I
score in On-drug phase was able to distinguish PD subjects
with and without history of falling, which is aligned with our
results for both drug phases. In addition, we showed that
FES-I can discriminate the two drug phases, the ability with
potential application for future studies to assess treatment
response in PD.
Since most of the participants in our study were in early
stage based on the modified Hoehn and Yahr staging, results
showed a low score of the FES-I and mild floor effect of this
score in both drug phases, which is in contrast to Jonasson’s
study (2014) in this population (in this study, PD patients
were older and at higher level on modified Hoehn and Yahr.)
[26]. Assessment in Off-drug phase is one of the major issues
that have always been used to provide more accurate
medication and evaluation clinical interventions in Parkin-
son’s disease [10]. Examination of psychometric properties of
this scale in the Off-drug phase for use in research and clinics
is another strength of this study. Limitations of this study are
the lack of evaluation of Levodopa dose equivalence and
identification of patients with motor fluctuations. Also, using
more appropriate tools for PD (e.g., the Fullerton Advanced
Balance Scale or the Mini-BESTest) to analyze the FES-I
convergent validity, carrying out confirmatory factor analy-
sis (CFA) for dimensionality, and higher size of the samples
are suggested for future studies addressing the properties of
the FES-I in PD patients with fluctuations.
5. Conclusion
In conclusion, our study suggests that the FES-I is a reliable
and valid scale for measuring fear of falling in individuals
Table 4: Correlation between total scores of Fall Efficacy Scale-International (FES-I) with other scales in people with idiopathic Parkinson’s
disease (n � 124).
Drug phase Scales VAS-FOF BBS FRT PDQ-39 (mobility) UPDRS-ADL
On FES-I 0.54 −0.71 −0.51 0.65 0.59Off 0.50 −0.70 −0.56 0.71 0.67
FES-I: Fall Efficacy Scale-International. VAS-FOF: Visual Analog Scale-Fear of Fall. BBS: Berg Balance Scale. FRT: Functional Reach Test. PDQ-39: Parkinson
Disease Questionnaire-39-Domain “Mobility”. UPDRS-ADL: Unified Parkinson’s disease Rating Scale-Activities of Daily Living. All coefficients, p< 0.001.
Table 2: Characteristics statistic of Fall Efficacy Scale-International (FES-I) in patients with idiopathic Parkinson’s disease (n � 124).
Drug phase Mean (±SD) Range Floor effect Ceiling effect Skewness SEM Cronbach’s α ICC (test-retest) (95% IC)
On 27.34 (11.32) 16–64 34.67% 1.61% 1.00 2.77 0.96 0.94 (0.90–0.96)
Off 33.38 (15.41) 16–64 21.77% 7.25% 0.64 4.62 0.98 0.91 (0.86–0.94)
SEM: standard error of measurement. 95% IC: 95% lower and upper confidence bounds for the ICC statistics are given in parentheses.
Table 3: Factor analysis for Fall Efficacy Scale-International (FES-I) in people with idiopathic Parkinson’s disease (n � 124).
On-drug phase Off-drug phase
Item of FES-I
Component (factor)
Item of FES-I Component (factor)
1 2 1
14 0.87 8 0.90
15 0.85 4 0.89
11 0.84 5 0.89
9 0.69 12 0.88
13 0.68 15 0.88
7 0.67 16 0.88
8 0.66 3 0.87
16 0.65 13 0.87
3 0.81 14 0.87
1 0.75 1 0.86
10 0.74 6 0.84
2 0.70 7 0.84
4 0.64 9 0.83
6 0.62 10 0.82
5 0.60 11 0.82
12 0.59 2 0.80
1: cleaning the house. 2: getting dressed or undressed. 3: preparing simple meals. 4: taking a bath or shower. 5: going to the shop. 6: getting in or out of a chair.
7: going up or down stair. 8: walking around in the neighborhood. 9: reaching for something above your head or on the ground. 10: going to answer the
telephone before it stops ringing. 11: walking on a slippery surface. 12: visiting a friend or relative. 13: walking in a place with crowds. 14: walking on an uneven
surface. 15: walking up or down a slope. 16: going out to a social event.
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with PD. Also, it is an appropriate scale for clinicians and
researchers to use during the On- and Off-drug phases.
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